24 April 2024 Quarterly Activity Report and Appendix 4C Doctor Care Anywhere Group PLC (ASX:DOC, “Doctor Care Anywhere” or “the Company”) is pleased to provide an update on trading and corporate activity for the quarter ended 31 March 2024 (“Q1 2024”)1. Executive Summary     Positive EBITDA in Q1, supporting the drive towards cash generation. 199,200 consultations delivered, up 11.4% on PcP and 14.2% QoQ, representing the highest number of quarterly consultations delivered in the Company’s history. Customer receipts in the quarter increased £1.9m vs PcP and £0.7m vs QoQ Revenue in H1 expected to grow at the upper end of 5-10% guidance. Operational Performance – KPIs Eligible Lives at Period End Activated Lives3 at Period End Consultations4 in Period Secondary Care Journeys5 in Period Repeat Patients6 in Period 2 Actual % increase / (decrease) on % increase / (decrease) on Q1 2024 000’s 3,009.7 1,055.8 199.2 11.0 145.6 Q1 2023 (PcP) Q4 2023 (QoQ) 9.4% 14.4% 11.4% 10.6% 17.1% (0.2%) 0.7% 14.2% 20.7% 9.1% Commentary Eligible Lives at the end of Q1 2024 were 3.01 million, up 9.4% on PcP, down 0.2% QoQ. At the end of Q1 2024, Activated Lives were 1.06 million, up 14.4% on PcP and 0.7% QoQ. Consultation volumes continued to grow year-on-year, with 199,200 consultations delivered in Q1 2024, up 11.4% on PcP and up 14.2% QoQ. The increase in consultation volumes on PCP was primarily driven by both growth in activated lives and the increase in capacity following the launch of the Mixed Clinical Workforce in June 2023. The increase QoQ is primarily driven by the onset of winter following a relatively mild Q4 2023. This Quarterly Activity Report and Appendix 4C is prepared in GBP in accordance with International Financial Reporting Standards in conformity with the requirements of the Companies Act 2006 (UK) and is unaudited. Figures expressed in Australian Dollars (“A$”) have been converted from British Pounds Sterling at an exchange rate of AUD:GBP 1:0.52 for the quarter ended 31 March 2024 and at 1:0.54 for the quarter ended 31 March 2023. 2 Eligible Lives represents the total number of people who have an entitlement to use DOC’s services. 3 Activated Lives represents the total number of people who “sign up” for DOC’s service and enter their personal details. 4 Consultations is the number of GP, ANP, Psychiatrist and Psychologist consultations delivered to patients over the period. 5 Secondary Care Journeys is the number of secondary care journeys completed by patients over the period following a referral from an initial GP or ANP consultation on the DCA platform. 6 Repeat Patients represents the number of consultations completed by patients who had previously completed an appointment. 1 1|Page Consultations by Quarter (000’s) 199,200 consultations represents the highest number of quarterly consultations delivered in the Company’s history. First Time Repeat 185 143 152 151 165 74 89 53 55 38 34 41 Q4 Q1 2020 2021 Q2 2021 Q3 2021 42 32 93 102 104 104 51 50 47 41 76 199 181 174 136 133 44 41 146 117 91 192 118 47 124 141 60 51 146 54 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2021 2022 2022 2022 2022 2023 2023 2023 2023 2024 Returning patients represented 73% of all consultations in the quarter, an increase of 6% vs PcP, but down 3% QoQ due to good growth in first time consultations. The Company completed 11,000 secondary care journeys in the period. As highlighted last quarter, DCA and AXA Health are reviewing the economics of the diagnostic pathways. DCA continues to consider opportunities to optimise the patient journey while managing claims costs for AXA Health and driving profitability. 2|Page Cash Position: Progress to Profitability and Net Cash Generation Q1 2023 £000 % increase /(decrease) QoQ £000 % increase /(decrease) versus PcP 10,191 9,520 7.0% 8,245 23.6% Other/Non-operating staff costs (2,370) (2,067) 14.7% (2,293) 3.4% R&D/Intellectual property costs (840) (1,024) (18.0%) (1,529) (45.1%) Operating costs (6,267) (6,135) 2.2% (6,378) (1.7%) Other administrative costs (2,239) (1,454) 54.0% (2,639) (15.2%) 114 439 (74.0%) 649 (82.4%) (1,411) (721) (95.7%) (4,217) (66.5%) Financing cash flows 77 (133) n/m 7,342 n/m Exchange gain/(loss) (16) (3) 433.3% (10) 60.0% (1,350) (857) 57.5% (4,266) (68.4)% Q1 2024 Q4 2023 Cash movements £000 Receipts from customers Other cash inflows Total operating and investing outflows Net cash flow Total operating and investing cash outflows fell by 66% vs PcP due to increased customer receipts and lower costs, and increased QoQ by £0.7 million, primarily driven by one off annual payments for insurance totalling £1.0m in Q1 2024. Further details are set out below:      Cash receipts from customers increased by 23.6% versus PcP driven by contractual price increases and increasing volumes, and by 7.0% QoQ primarily driven by an increase in consultation volumes. Staff cash spend increased by 3.4% versus PcP, and by 14.7% QoQ, due to the timing of one-off bonus payments in the period. R&D and intellectual property cash spend reduced by 45.1% versus PcP, primarily due to a reduction in the Technology team, and by 18.0% QoQ, primarily due to timing of payments. Other administrative costs cash spend fell by 15.2% versus PcP due to tight cost controls, but increased by 54.0% QoQ, primarily due to the £1.0m insurance payment. Other cash inflows in Q1 2024 relate to a VAT receipt in the period; however the claim was significantly less than the prior quarter due to timing of receipt of invoices. The overall cash outflow for the business in Q1 2024 was £1.4 million (A$2.6 million), a reduction of 68.4% versus PcP, and an increase of 57.5% QoQ, the quarterly change being largely due to the £1.0m insurance payment offset by increased customer receipts. The Company exited the quarter with £4.7 million (A$9.1 million) of cash on hand at 31 March 2024. Activities since previous market update Following the market update issued as part of the Appendix 4C release on 31 January 2024, an update is provided below on key matters: Operational and financial 3|Page - As announced on 6 March 2024, the Company has confirmed Ben Kent in role as Chief Executive Officer and appointed Seema Sangar as Chief Financial Officer. - As announced on 19 March 2024, the Company has launched a partnership with home health test provider Medichecks. DCA has become Medichecks’ preferred provider of GP consultations for customers seeking advice on their test results. - During 1Q 2024, the Company was pleased to reach agreement with Nuffield Health in relation to a historical commercial contract. No service credits will be payable to Nuffield Health relating to this period. Guidance - DCA is pleased to confirm that it has hit guidance of being EBITDA positive in Q1 2024. Achieving this milestone demonstrates continuing focus on our goal of profitable growth. - Additionally, as at the date of this report: o DCA remains on track to be underlying cash generative in 2H 2024. o DCA remains on track to meet its guidance issued in February 2024, being 5-10% revenue growth in 1H 2024 vs. 1H 2023, which is subject to the assumptions and dependencies accompanying that guidance. After a strong Q1 performance, DCA now expects to trade at the upper end of this range in 1H 2024. The Company will present further details on its strategic direction for 2024 and beyond at its Annual General Meeting on Monday 29 April 2024 at 17:00 (AEST)/ 08.00 (BST) Other As required by ASX Listing Rule 4.7C.3, the Company discloses that payments to related parties in the period totalled £0.08 million, representing payment of Director Fees to Non-Executive Directors (including pension and payroll tax payments), the same value as in the prior quarter. This update must be read as a whole and is subject to the disclaimer that it:    Is subject to the assumptions referred to above and, if any of those assumptions are not met, actual results may differ from this guidance; Is not a prediction or guarantee of future performance; and Involves known and unknown risks, uncertainties and other factors which are beyond the Company’s control, and which may cause actual results to differ from this guidance. The Company is not liable for the accuracy and/or correctness of this information and any differences between the guidance and actual outcomes. Corporate Overview     366,771,846 shares/CDIs on issue Market capitalisation of A$22.73m at date of report release £4.7m (A$9.0m) cash at 31 March 2024 £10.6m (A$20.4m) in debt under the convertible loan at 31 March 2024. - ENDS This ASX announcement has been authorised for release by the Board of Directors. 4|Page About Doctor Care Anywhere: Doctor Care Anywhere Group PLC is one of the UK’s largest private providers of telehealth services. The Company works with insurers, healthcare providers and corporate customers to connect patients to a range of digitally enabled telehealth services on its proprietary platform. It is committed to delivering the best possible patient experience and clinical care through digitally enabled, joined up, evidence-based pathways. 5|Page Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Name of entity Doctor Care Anywhere Group PLC ARBN Quarter ended (“current quarter”) 645 163 873 31 March 2024 Consolidated statement of cash flows 1. Cash flows from operating activities 1.1 Receipts from customers 1.2 Payments for Current quarter £’000 Year to date (3 months) £’000 10,191 10,191 (522) (522) (6,267) (6,267) (77) (77) - - (e) staff costs (2,370) (2,370) (f) administration and corporate costs (2,162) (2,162) - - 21 21 (a) research and development (b) product manufacturing and operating costs (c) advertising and marketing (d) leased assets 1.3 Dividends received (see note 3) 1.4 Interest received 1.5 Interest and other costs of finance paid - - 1.6 Income taxes paid - - 1.7 Government grants and tax incentives - - 1.8 Other (provide details if material) 93 93 1.9 Net cash from / (used in) operating activities (1,093) (1,093) 2. Cash flows from investing activities 2.1 Payments to acquire or for: (a) entities - - (b) businesses - - (c) property, plant and equipment - - (d) investments - - (318) (318) - - (e) intellectual property (f) other non-current assets 6|Page Consolidated statement of cash flows 2.2 Current quarter £’000 Year to date (3 months) £’000 Proceeds from disposal of: (g) entities - - (h) businesses - - (i) property, plant and equipment - - (j) investments - - (k) intellectual property - - (l) other non-current assets - - 2.3 Cash flows from loans to other entities - - 2.4 Dividends received - - 2.5 Other - - 2.6 Net cash from / (used in) investing activities (318) (318) 3. Cash flows from financing activities 3.1 Proceeds from issues of equity securities (excluding convertible debt securities) - - 3.2 Proceeds from issue of convertible debt securities - - 3.3 Proceeds from exercise of options - - 3.4 Transaction costs related to issues of equity securities or convertible debt securities (103) (103) 3.5 Proceeds from borrowings 10,610 10,610 3.6 Repayment of borrowings (10,430) (10,430) 3.7 Transaction costs related to loans and borrowings - - 3.8 Dividends paid - - 3.9 Other (provide details if material) - - 3.10 Net cash from / (used in) financing activities 77 77 4. Net increase / (decrease) in cash and cash equivalents for the period 4.1 Cash and cash equivalents at beginning of period 6,060 6,060 (1,093) (1,093) 4.2 Net cash from / (used in) operating activities (item 1.9 above) 4.3 Net cash from / (used in) investing activities (item 2.6 above) (318) (318) 4.4 Net cash from / (used in) financing activities (item 3.10 above) 77 77 7|Page Consolidated statement of cash flows Current quarter £’000 Year to date (3 months) £’000 4.5 Effect of movement in exchange rates on cash held (16) (16) 4.6 Cash and cash equivalents at end of period 4,710 4,710 5. Reconciliation of cash and cash equivalents Current quarter £’000 Previous quarter £’000 at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts 5.1 Bank balances 4,710 6,060 5.2 Call deposits - - 5.3 Bank overdrafts - - 5.4 Other (provide details) - - 5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above) 4,710 6,060 6. Payments to related parties of the entity and their associates 6.1 Aggregate amount of payments to related parties and their associates included in item 1 84 6.2 Aggregate amount of payments to related parties and their associates included in item 2 - Current quarter £'000 Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments. 8|Page 7. Financing facilities Note: the term “facility’ includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity. Total facility amount at quarter end £’000 Amount drawn at quarter end £’000 10,610 10,610 7.1 Loan facilities 7.2 Credit standby arrangements - - 7.3 Other (please specify) - - 7.4 Total financing facilities - 10,610 7.5 Unused financing facilities available at quarter end 7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. - The loan facility is as announced by the Company on 12 January 2024: https://wcsecure.weblink.com.au/pdf/DOC/02762058.pdf The Convertible Notes bear no interest and may be converted into CDIs by the Convertible Noteholders at any time (provided more than 60 days have passed since the holder’s previous conversion) at an issue price of £0.0459 (equivalent to A$0.0875, based on exchange rate of 8 December 2023, being a premium of 94% to the closing price of the Company’s CDIs on the ASX of A$0.045 on 11 December). Doctor Care Anywhere may redeem all outstanding Convertible Notes in full on or after 1 January 2026 by repaying the outstanding principal. This loan was paid off in January 2024 following the completion of the convertible loan financing arrangement. 8. Estimated cash available for future operating activities £’000 8.1 Net cash from / (used in) operating activities (item 1.9) (1,093) 8.2 Cash and cash equivalents at quarter end (item 4.6) 4,710 8.3 Unused finance facilities available at quarter end (item 7.5) 8.4 Total available funding (item 8.2 + item 8.3) 8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1) 4,710 4 Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5. 8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions: 8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not? Answer: 9|Page 8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful? Answer: 8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis? Answer: Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered. 10 | P a g e Compliance statement 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A. 2 This statement gives a true and fair view of the matters disclosed. Date: 24 April 2024 Authorised by: Board of Directors 11 | P a g e